LIF and cancer: To evaluate cellular response to exogenous LIF stimulation, we treated cancer cells with recombinant human LIF pre-labeled with ATTO 488 and found that cLIF cells appeared resistant to the uptake of LIF, unlike that observed in WT or LIF+/− cells (Fig. 2f).